Bannerbild German Brest Group

GBG Research at ESMO Virtual Meeting 2020

14.09.2020

Data of several GBG studies will be presented at the upcoming ESMO Virtual Meeting 2020, which will take place from 19 to 21 September 2020.

ePoster #248TiP Date: 17.09.2020
Speaker: Sibylle Loibl (Neu-Isenburg, Germany)
GeparDouze: A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
Loibl S, Rastogi P, Seiler S, et al.

ePoster # 176P Date: 17.09.2020
Speaker: Jan Hauke (Köln, Germany)
GeparOLA; Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
Hauke J, Ernst C, Fasching PA, et al.

Mini oral presentation #168MO Date: 18.09.2020 Session: Mini Oral - Breast cancer, early stage
Chairs: Hope S. Rugo (San Francisco, CA, United States of America), Prudence Francis (Melbourne, VIC, Australia), Shaheenah Dawood (Dubai, United Arab Emirates)
Speaker: Theresa Link (Dresden, Germany)
GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status
Link T, Blohmer J-U, Just M, et al.

Oral presentation #160O Date: 20.09.2020 Time: 12:54 - 13:06 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Andreas Schneeweiss (Heidelberg, Germany)
GeparOcto: Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Schneeweiss A, Möbus V, Tesch H, et al.

EXTERNAL # LBA12 Date: 20.09.2020 Time: 13:26 - 13:38 Room: Channel 3
Chairs: Javier Cortés (Barcelona, Spain), Sherko Kümmel (Essen, Germany)
Speaker: Erica L. Mayer (Boston, United States of America)
PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer


ESMO 2020

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd